Search results for "IVU"
showing 10 items of 506 documents
Comunicación de la responsabilidad social corporativa (RSC) en redes sociales
2018
El auge de la Responsabilidad Social Corporativa (RSC) de la mano del surgimiento y desarrollo de la web 2.0 han propiciado cambios en la comunicación contable de información no financiera dirigida a un amplio espectro de stakeholders, que han repercutido en el uso de diversas herramientas y aplicaciones como las redes sociales -creadas para favorecer y fortalecer las relaciones sociales, incrementar la interacción y buscar una participación activa del usuario a través de la co-creación de contenidos-(Fieseler and Fleck, 2013). Con ello, las dinámicas de accountability corporativa han sido trasladadas de los medios tradicionales hacia medios interactivos que podrían promover el stakeholder …
Latvijas Vēstures Institūta Žurnāls. 2014, Nr. 3 (92)
2014
Valsts kultūrkapitāla fonds
El Aula de Física Experimenta de la Universitat de València: más de una década de iniciativas para Secundaria
2013
se encuentra mayor información sobre el tema en http://www.uv.es/experimenta Desde la Facultad de Física de la Universitat de València hace ya tiempo que se vienen promoviendo iniciativas que pretenden mejorar la docencia y el aprendizaje de la Física, incidiendo de forma especial en los aspectos fenomenológicos y experimentales en conexión con los modelos teóricos, así como en las relaciones con otras ciencias y las aplicaciones tecnológicas. Estas iniciativas, surgidas a propuesta del Grupo de Trabajo de Física Arquímedes, se aglutinan alrededor del Aula Experimenta, y se centran en la formación del profesorado no universitario y en la colaboración entre la universidad y los centros de Ed…
Divulgazioni, plagi e incisioni di architettura nel Seicento europeo. Il caso della Bibbia di Melchior Küsel
2018
DIVULGAZIONI, “PLAGI” E INCISIONI DI ARCHITETTURA NEL SEICENTO EUROPEO. IL CASO DELLA BIBBIA DI MELCHIOR KÜSEL Nel 1908 la storica dell’arte austriaca Erika Tietze-Conrat pubblicava un articolo su sull’ Icones Biblicae Veteris et Novi Testamenti…, una bibbia illustrata edita ad Augsburg nel 1680 dall’incisore tedesco Melchior Küsel. La studiosa aveva colto come la peculiarità di questa Bilderbibel risiedesse non soltanto nelle 241 tavole che Küsel aveva inserito come corredo e sfondo delle molte storie tratte dal vecchio e dal nuovo testamento, quanto nella selezione delle fonti iconografiche. La quasi totalità delle incisioni non era frutto di invenzioni di Küsel che aveva realizzato nuovi…
Subtemporal Keyhole Approach to the Suprasellar and Petroclival Region: Microanatomic Considerations and Clinical Application
1997
OBJECTIVE: To minimize surgical invasiveness, the keyhole concept is applied to the subtemporal approach. METHODS: Anatomic features were studied in 14 sides of adult cadaver heads, and the technique was used in 162 interventions. Although most of the lesions treated were 3 cm in size or smaller, larger lesions were also treated using this technique. In some cases, if needed, an endoscope-assisted microsurgical technique was used. RESULTS: The cadaveric study provided intimate experience with the microsurgical anatomy of the approach. The 162 consecutive patients who were operated on harbored various types of lesions; the most recent 43 consecutive interventions were investigated in detail.…
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy
2005
In hepatitis B virus (HBV) cirrhosis patients on long-term lamivudine (LAM), the relationships between HBV suppression, development of viral resistance and disease outcome are unclear. We analysed the dynamic of serum HBV-DNA and its relationship with the clinical course of 59 patients (52 males, mean age 51.4 ±8.4 years, 12 HBeAg positive and 47 HBeAg negative, and 57 genotype D and two genotype A) with cirrhosis (45 in Child-Turcotte-Pugh class A) and high levels of serum HBV-DNA (median 14.7x107 genomes/ml) treated with LAM [median (range): 44 (15–78) months]. A total of 50 patients (84.7%) achieved a virological response (serum HBV-DNA negative by PCR) during the first 6 months of ther…
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance
2004
The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine is well documented. However. its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known. In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months. All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain. During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of viral resistance, generally showing aggressive…
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years
2012
Background & Aims In long-term responder patients, it is unclear whether lamivudine (LAM) monotherapy should be continued or switched to a high-genetic-barrier analogue. This study aims at assessing LAM efficacy over a 5-year period and the residual risk of drug resistance. The rate of HBsAg clearance and LAM long-term safety profile were also evaluated. Methods One hundred and ninety-one patients with chronic HBeAg-negative hepatitis B successfully treated with LAM monotherapy for at least 5years were included. Biochemical and virological tests were assessed every 3months in all patients and HBsAg quantification was performed in 45/191. Reverse-transcriptase (RT) region was directly sequen…
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
2013
Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…